# Study of a Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine

> **NCT04962893** · PHASE2 · COMPLETED · sponsor: **Ihsan GURSEL, PhD, Prof.** · enrollment: 349 (actual)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** SARS-CoV-2 VLP Vaccine-Wuhan
- **BIOLOGICAL:** SARS-CoV-2 VLP Vaccine-Alpha (British) variant
- **BIOLOGICAL:** SARS-CoV-2 VLP Vaccine-Wuhan+Alpha variant

## Key facts

- **NCT ID:** NCT04962893
- **Lead sponsor:** Ihsan GURSEL, PhD, Prof.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-26
- **Primary completion:** 2022-01-16
- **Final completion:** 2022-01-16
- **Target enrollment:** 349 (ACTUAL)
- **Last updated:** 2022-05-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04962893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04962893, "Study of a Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04962893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*